-
Dendrosomal Nanocurcumin Targets Wnt Pathway in Breast Cancer
07 Aug 2025 11:32 GMT
… in validating the safety, pharmacokinetics, and efficacy of dendrosomal … PIWIL2 in MCF-7 breast cancer cells. Med Oncol 42, 381 ( … for drug deliveryMCF-7 breast cancer cell studiesnanotechnology in oncologyovercoming cancer treatment resistancePIWIL2 …
-
'This therapy can be applied to thousands': UK researcher makes breakthrough in breast cancer research
07 Aug 2025 11:10 GMT
… protein can actually contribute to breast cancer metastasis, help the cancer cells … was able to test a drug against HSP47 to block its … said the mortality rate in breast cancer in the Commonwealth is … research will go to clinical trial in the near future. He …
-
Cancer Cachexia Clinical Trial Pipeline Shows Potential With Active Contributions From 18+ Key Companies Delveinsight
07 Aug 2025 17:07 GMT
… Cancer Cachexia Clinical Trial Pipeline Shows Potential … CSPC Pharmaceutical Group Limited announced that the antibody drug … 40% in those with breast cancer, sarcoma, leukemia, or … cancer cachexia treatments, visit @ Cancer Cachexia Drugs Table of …
-
ProteinQure Receives Regulatory Clearance to Initiate Phase I Trial for PQ203 in the U.S. and Canada; Granted FDA Fast Track Designation
07 Aug 2025 14:33 GMT
… Drug Administration (FDA) and Health Canada to initiate a Phase I clinical trial … evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer … for patients with triple negative breast cancer, recognizing the therapy’s …
-
Big Pharma-Backed mRNA Startup Bags $153M Series B Amid Policy Headwinds
07 Aug 2025 16:02 GMT
… of the biggest names in pharma, including Eli Lilly, Amgen and … , particularly melanoma and triple-negative breast cancer.
Uniquely, Strand’s approach makes … monotherapy has shown signals of treatment response, Strand reported in May …
-
Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk
07 Aug 2025 13:05 GMT
… Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational … on placebo. The overall treatment discontinuation rates were 21. … .
The U.S. pharma giant reported second-quarter … realized prices.
Verzenio (a breast cancer drug) revenue increased 12% to …
-
Duloxetine Blocks Breast Cancer via AKT and Apoptosis
07 Aug 2025 05:42 GMT
… well-established drugs with known … breast cancer but also illustrates the transformative potential of drug … -mediated apoptosis. Med Oncol 42, 364 … breast cancer treatmentmultimodal cancer treatmentnovel therapeutic approachesoncology pharmacology …
-
Breast cancer researchers unite to prevent recurrence
07 Aug 2025 01:12 GMT
… efficiencies of discovery in early breast cancer treatment and ultimately has the … developing a neoadjuvant (treatment given before surgery) trial platform,” he explained … trial platform will focus on giving patients with high-risk early breast cancer …
-
Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint Inhibitor
07 Aug 2025 00:31 GMT
Newswise — IRVING, Texas, Aug. 6, 2025 -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a new study in Communications Medicine, a Nature portfolio journal, …
-
AI predicts risk of breast cancer two times more accurately than human doctors
06 Aug 2025 22:37 GMT
… Breakthrough Device designation from the FDA, potentially speeding its path to … for successful breast cancer treatment. The five-year survival rate for breast cancer caught in … developers are planning a clinical trial at the Siteman Cancer Center …